Rewriting Life

Biotech Briefs

REGULATIONS

Danvers, MA–based Abiomed has sought approval from the U.S. Food and Drug Administration to market its AbioCor artificial heart under a humanitarian-device exemption. Such an exemption would allow doctors to implant the heart, which has been tested on just 14 people so far, in not more that 4,000 patients suffering from end-stage heart failure.

MILESTONE

This story is part of our November 2004 Issue
See the rest of the issue
Subscribe

The European Commission has given the green light for farmers throughout the European Union to buy and plant 17 varieties of genetically modified corn – the first time biotech crops have received such EU-wide authorization. All food made with the corn varieties, which St. Louis agricultural-products company Monsanto engineered to resist a pest called the corn borer, will be labeled as genetically modified.

IPO

Seattle’s Corus Pharma has filed preliminary papers with the U.S. Securities and Exchange Commission for an initial public offering. Backed in part by Cascade Investment, Bill Gates’s private fund, Corus is testing inhaled treatments for asthma and cystic fibrosis in humans.

ACQUISITION

Palo Alto, CA’s Agilent Technologies announced an agreement to acquire software firm Silicon Genetics of Redwood City, CA. The acquisition reflects an effort by Agilent – a leading maker of life-sciences and chemical-research equipment – to strengthen its position in bioinformatics.

ADVANCE

Researchers at King’s College London have created human embryonic stem cells that carry a mutation that causes cystic fibrosis. The cells could offer new opportunities for scientists to study the devastating genetic disorder and develop new treatments for it.

ETHICS

As genetics researchers continue to home in on genes that affect behavior and contribute to neurological conditions such as schizophrenia and autism, Stanford University is launching a center to study the ethical consequences of such research. One project planned for the new Center for Integration of Research on Genetics and Ethics: a Web-based ethics consultation service for geneticists.

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.

Subscribe today

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Premium.
  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look. Exclusive early access to stories.

    Insider Conversations. Listen in as our editors talk to innovators from around the world.

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.